Collegium Reports Third Quarter Financial Results and Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/25/2026
- Nasdaq, S&P end lower as tech stocks fall
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
Collegium (COLL) Xtampza ER Sales More than Double Expectations - William Blair
November 9, 2017 9:50 AM ESTWilliam Blair analyst Tim Lugo reiterated an Outperform rating on Collegium Pharmaceutical (NASDAQ: COLL) following Q3 results which showed Xtampza ER sales for the third quarter came in at $11.95 million, well above our expectation of $4.8 million and consensus of $5.3 million. Lugo notes that... More
